Original Research
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
May 11, 2022
This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.
